09 August 2007
Successful results from CSD500 condom study
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for the consumer healthcare market, is pleased to announce positive results from a user study of CSD500, Futura’s novel product to help men maintain a full erection when wearing a condom. The study, equally funded by Futura and its marketing and distribution partner SSL International plc (SSL), successfully met its primary endpoint of demonstrating a firmer erection through the use of the CSD500 condom compared with a standard condom. This result was highly statistically significant.
The study’s secondary endpoints of increased penile size and a longer-lasting sexual experience also revealed positive, statistically significant data. These results from the double-blind, randomised, cross-over study will complete the regulatory package for CSD500.
The study included 108 healthy couples, the men of which had at some time experienced a loss or partial loss of erection whilst using standard condoms. A good safety and tolerability profile was reported for CSD500.
James Barder, Futura’s Chief Executive, said: “I am delighted by these highly statistically significant study results, which give us confidence that the CSD500 product will gain marketing approval and, once launched, be a commercial success. We look forward to continuing to work closely with SSL.”
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive
Anthony Clayden, Finance Director
+44 (0) 1483 685 670
james.barder@futuramedical.co.uk
www.futuramedical.co.uk
Canaccord Adams
Mark Ashurst / Tyler Broda
Tel: + 44 (0) 20 7050 6500
For any media enquiries please contact:
Buchanan Communications Limited
Mark Court
markc@buchanan.uk.com
Rebecca Dietrich
rebeccad@buchanan.uk.com
+44 (0) 20 7466 5000
Notes
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
The information pursuant to AIM rule 26 is now available at Futura’s website:
www.futuramedical.co.uk